809 results on '"Pietschmann, Thomas"'
Search Results
2. Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor
3. Discovery of the Pendulisporaceae: An extremotolerant myxobacterial family with distinct sporulation behavior and prolific specialized metabolism
4. The role of human lipoproteins for hepatitis C virus persistence
5. Repurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targets
6. Unlocking the Antiviral Arsenal: Multiparametric Optimization of Small-Molecule Inhibitors against RSV and hCoV-229E
7. Unraveling the dynamics of hepatitis C virus adaptive mutations and their impact on antiviral responses in primary human hepatocytes
8. IRIS: Infection with RespIratory Syncytial Virus in infants—a prospective observational cohort study
9. Target capture sequencing reveals a monoclonal outbreak of respiratory syncytial virus B infections among adult hematologic patients
10. Entwicklungsansätze für Impfstoffe gegen Hepatitis-C-Virus-Infektionen
11. Reverse genetics systems for contemporary isolates of respiratory syncytial virus enable rapid evaluation of antibody escape mutants
12. Children and Adolescents’ Behavioral Patterns in Response to Escalating COVID-19 Restriction Reveal Sex and Age Differences
13. Fluvastatin mitigates SARS-CoV-2 infection in human lung cells
14. Landscape of protein-protein interactions during hepatitis C virus assembly and release
15. A condensate-hardening drug blocks RSV replication in vivo
16. Hepatitis C virus cell culture adaptive mutations enhance cell culture propagation by multiple mechanisms but boost antiviral responses in primary human hepatocytes
17. Blood T cell phenotypes correlate with fatigue severity in post-acute sequelae of COVID-19
18. Joint statement in support of hepatitis C human challenge studies
19. Deep mining of the Sequence Read Archive reveals major genetic innovations in coronaviruses and other nidoviruses of aquatic vertebrates.
20. Enhanced monitoring and detection of recent genotype 3 hepatitis E virus infection through urine antigen testing
21. Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model
22. Virucidal activity of oral, hand and surface disinfectants against respiratory syncytial virus
23. Single-nucleotide variants in human CD81 influence hepatitis C virus infection of hepatoma cells
24. A molecular tweezer antagonizes seminal amyloids and HIV infection.
25. A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors
26. Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants
27. The decrease of HCV-specific neutralizing antibody responses after DAA therapy is associated with weak envelope-specific CD4 T cell immunity
28. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
29. Maturation of secreted HCV particles by incorporation of secreted ApoE protects from antibodies by enhancing infectivity
30. Immune protection against reinfection with nonprimate hepacivirus
31. Virucidal Activity of World Health Organization–Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses
32. Mutations That Permit Efficient Replication of Hepatitis C Virus RNA in Huh-7 Cells Prevent Productive Replication in Chimpanzees
33. Joint statement in support of hepatitis C human challenge studies
34. Christoph Willibald Gluck: Bilder Mythen Diskurse
35. Hepatitis D virus infection, innate immune response and antiviral treatments in stem cell‐derived hepatocytes.
36. Target-directed dynamic combinatorial chemistry affords inhibitors of Nsp10 as potential antivirals against SARS-CoV-2
37. Persicamidine – Außergewöhnliche Sesquarterpenoide mit potenter antiviraler Bioaktivität gegen Coronaviren
38. Persicamidines—Unprecedented Sesquarterpenoids with Potent Antiviral Bioactivity against Coronaviruses
39. mRNA based expression of Hepatitis E specific neutralizing antibodies in liver cells as therapeutic option
40. The Interplay of antigen and antibody in HEV infection
41. Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages
42. Thiamyxine: Struktur und Biosynthese myxobakterieller RNA‐Virus Inhibitoren**
43. Thiamyxins: Structure and Biosynthesis of Myxobacterial RNA‐Virus Inhibitors**
44. Decoding protein networks during virus entry by quantitative proteomics
45. Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity
46. Molecular characteristics and successful management of a respiratory syncytial virus outbreak among pediatric patients with hemato-oncological disease
47. Thiamyxins: Structure and Biosynthesis of Myxobacterial RNA-Virus-Inhibitors
48. Hepatitis D virus infection of stem cell-derived hepatocytes triggers an IFN- and NFκB-based innate immune response unable to clear infection
49. Cell Culture Systems for Hepatitis C Virus
50. A novel class of glycan-specific human monoclonal antibodies neutralizing the hepatitis E virus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.